186 results for "Microdosing"
Psilocybin microdosing in the United States: Insights from a nationally representative survey
Addiction – March 08, 2026
Summary
Over 8.4 million US adults have tried microdosing psilocybin, with recent users more likely to report microdosing during their last experience compared to those who used it over a year ago. Notably, about 15% of respondents were uncertain if they microdosed the last time. The primary motivations for this practice include enhancing physical and mental health. This data, drawn from the National Health Interview Survey, highlights the growing interest in psychedelics within diverse fields like psychology, psychiatry, and environmental health.
Abstract
At least 8.4 million US adults have microdosed psilocybin in their lifetime. Those who have used psilocybin within the past year are more likely to...
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
Journal of Psychopharmacology – August 12, 2023
Summary
Chronic microdosing of psychedelics like Lysergic acid diethylamide and Psilocybin may pose a heart valve risk. Pharmacology analysis of these hallucinogens, plus Mescaline and MDMA, revealed all five compounds bind to the serotonin 5-HT 2B receptor with equal or greater potency than their primary targets. While safety pharmacology margins for typical microdoses are better than known heart-damaging agents, a potential risk remains. Forensic Toxicology and Drug Analysis show MDMA's link to valvular heart disease at full doses. This insight into neurotransmitter receptor influence on behavior informs future drug studies and medicine.
Abstract
Psychedelic microdosing is the practice of taking very low doses of psychedelic substances, typically over a longer period of time. The long-term s...
Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration.
Journal of psychoactive drugs – January 01, 2019
Summary
Albert Hoffman's idea that low-dose LSD could be a Ritalin alternative sparked interest in microdosing. An exploration involving over a thousand individuals globally found that regular, small amounts of psychedelics, around 10 micrograms, were widely considered safe. Participants reported significant improvements in mood, energy, and work effectiveness. Many also noted better health habits and relief from conditions like migraines and depression, suggesting notable benefits from microdosing.
Abstract
Albert Hoffman suggested that low doses of LSD might be an appropriate alternative to Ritalin. Following this possibility, a systematic exploration...
Less is more? A review of psilocybin microdosing
Journal of Psychopharmacology – September 16, 2024
Summary
Definitive conclusions on psilocybin microdosing, a hallucinogen derived from alkaloids, remain elusive despite its potential in Medicine. A review of 40 studies and 8 grey literature websites, found via databases like MEDLINE, reveals a critical lack of robust evidence in Clinical psychology. Most findings stem from observational studies, with sparse clinical trials. Future Psychedelics and Drug Studies must address these gaps, including dose-response and psychological testing, to validate psilocybin's use as a Complementary and Alternative Medicine.
Abstract
Background: The applications of psilocybin, derived from ‘magic mushrooms,’ are vast, including a burgeoning practice known as microdosing, which r...
Modulation of long-term potentiation following microdoses of LSD captured by thalamo-cortical modelling in a randomised, controlled trial.
BMC neuroscience – February 05, 2024
Summary
Tiny doses of lysergic acid diethylamide (LSD) may subtly rewire brain connections, revealed through advanced brain imaging. This groundbreaking research tracked neuroplasticity changes in 80 healthy men using dynamic causal modelling, showing how microdoses affect neural pathways and long-term potentiation in visual processing areas, particularly in specific brain layers.
Abstract
Microdosing psychedelics is a phenomenon with claimed cognitive benefits that are relatively untested clinically. Pre-clinically, psychedelics have...
Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing
Scientific Reports – January 21, 2021
Summary
After four weeks, 81 individuals microdosing psychedelics reported improved mood, reduced anxiety, and enhanced mental health, reaching a key clinical endpoint. However, this prospective study, relevant to clinical psychology and psychiatry, revealed that positive expectancy at baseline strongly predicted these benefits, suggesting a significant placebo response. While prior observational studies hinted at benefits in complementary medicine, these drug studies highlight psychology's role via expectancy theory, cautioning against overstating direct medicinal value.
Abstract
Abstract Psychedelic microdosing describes the ingestion of near-threshold perceptible doses of classic psychedelic substances. Anecdotal reports a...
Microdosing of Psychoactive Substances in Business Practice
Businesses – December 06, 2021
Summary
Remarkably, microdosing **drugs of abuse** like LSD and cocaine allows individuals to sustain a subtle psychoactive effect through the work week, avoiding significant behavioral changes or withdrawal. This **dosing** strategy, unlike standard use, even sees stimulants require progressively lower doses over time for the same effect, a fascinating **pharmacology** insight. Conversely, **psychedelics** develop resistance. Through **case studies** examining **psychology** and initial **biochemical analysis** in corporate environments, this approach's influence on business managers and creatives is being explored, revealing a unique pattern of substance interaction.
Abstract
Abusing psychoactive substances has been a popular sport in the business world since the mid-19th century. First, they were appreciated for their s...
Microdosing Psychedelics: Current Evidence From Controlled Studies.
Biological psychiatry. Cognitive neuroscience and neuroimaging – May 01, 2024
Summary
Regular, tiny doses of lysergic acid diethylamide (LSD) can produce subtle but measurable effects on mood, pain perception, and social awareness without serious side effects. Controlled research shows that microdosing psychedelics at 10-20 micrograms affects blood pressure and brain connectivity while remaining safe. Lower doses of 5 micrograms showed no noticeable effects.
Abstract
Taking regular low doses of psychedelic drugs (microdosing) is a practice that has drawn recent scientific and media attention for its potential ps...
The therapeutic potential of microdosing psychedelics in depression
Therapeutic Advances in Psychopharmacology – January 01, 2020
Summary
Microdosing psychedelics like LSD and psilocybin shows subtle cognitive benefits, potentially offering new avenues for depression treatment. A review of 14 experimental drug studies found small doses (e.g., 10-20 mcg LSD) subtly improve thinking and affect brain regions. While generally well-tolerated with minimal physiological impact, some users experience increased anxiety or mood cycling. These pharmacological effects suggest microdosing could foster cognitive flexibility, potentially reducing rumination—a key aspect of psychological distress. Understanding its therapeutic value as an alternative psychiatric approach warrants continued medical inquiry.
Abstract
Microdosing psychedelics is the repeated use of small doses of, for example, lysergic acid diethylamide (LSD) and psilocybin, typically for a few w...
Is Microdosing a Placebo?
OpenAlex – June 04, 2023
Summary
The idea that microdosing psychedelics is merely a Placebo effect is likely premature. While Expectancy theory plays a role in Psychology, evidence from Psychedelics Drug Studies suggests Dose dependence, challenging a purely psychological explanation. Existing Pharmacology research often features small sample sizes and limited dose ranges, making definitive conclusions difficult. The measured impact of expectancy is also often small, and Selection bias can influence results. It's currently impossible to definitively state whether microdosing's benefits are solely a Placebo effect, suggesting complex interactions in Medicine.
Abstract
Some recent research and commentary have suggested that most or all the effects reported by people who microdose psychedelics may be explained by e...
Evaluating the Potential of Microdosing 1cp-LSD for the Treatment of Canine Anxiety: A One-Month Case Study.
Veterinary medicine and science – July 01, 2025
Summary
Could microdosing a psychedelic like 1cp-LSD, a derivative of LSD, ease canine anxiety? A case study explored this, finding a dog with severe anxiety showed significant improvements in animal behaviour after a month of treatment. Owners reported less destructive actions and reduced vocalization. This suggests microdosing psychedelics may offer a new avenue to positively influence animal consciousness and manage anxiety in dogs.
Abstract
This pilot study explored the potential of microdosing 1-cyclopropionyl-d-lysergic acid diethylamide (1cp-LSD) to treat canine anxiety. A single-ca...
Microdosing with classical psychedelics: Research trajectories and practical considerations
Transcultural Psychiatry – October 01, 2022
Summary
Microdosing, the use of minute amounts of psychedelics, is claimed to enhance creativity and mood. Psychology explores how substances like psilocybin, lysergic acid diethylamide, and mescaline—compounds often from chemical synthesis or natural alkaloids—influence consciousness and perception. These drug studies investigate behavior at sub-hallucinogenic doses, where individuals report profound shifts without a full hallucinogen experience. Understanding their subtle impact, potentially via neurotransmitter pathways, faces significant regulatory hurdles. The field aims to distinguish genuine effects from expectation.
Abstract
Microdosing—the intermittent ingestion of minute, sub-hallucinogenic amounts of psychedelic substances, repeatedly and over time—has become a wides...
Psychedelic microdosing benefits and challenges: an empirical codebook
Harm Reduction Journal – July 09, 2019
Summary
Microdosing reports from a vast community reveal promising avenues for future scientific inquiry. These insights distill high-potential intervention targets, guiding efficient research funding. Focusing on substances like Psilocybin and Lysergic acid diethylamide, popular hallucinogens, this work bridges Psychology and Pharmacology. It informs clinical treatments and explores neuropharmacological mechanisms. Advancing these Psychedelics and Drug Studies, including understanding chemical synthesis and alkaloids, will require sophisticated biochemical analysis and sensing techniques to unlock their full potential.
Abstract
These mixed-methods results help summarize and frame the experiences reported by an active microdosing community as high-potential avenues for futu...
Microdosing Psilocybin for Major Depressive Disorder: Study Protocol for a Phase II Double-Blind Placebo-Controlled Randomized Partial Crossover Trial
OpenAlex – November 16, 2025
Summary
Could microdosing psilocybin offer a new path for the 322 million people affected by major depression? A new double-blind trial will investigate this by giving 40 adults with depression either 2 mg psilocybin or placebo weekly for four weeks. All participants then receive psilocybin for another four weeks. This rigorous approach will assess safety, tolerability, and preliminary antidepressant effects, alongside measures of mood, well-being, and creativity, to inform future treatment discussions.
Abstract
Background: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of ...
Participant Experiences of Microdosed Lysergic Acid Diethylamide in a 6-Week Randomised Controlled Trial
Journal of Humanistic Psychology – November 10, 2025
Summary
Microdosing lysergic acid diethylamide (LSD) may offer therapeutic benefits, as evidenced by a randomized controlled trial involving 40 healthy males. Participants took 10 µg of LSD every third day for six weeks, leading to themes like improved mood, enhanced social interactions, and increased mindfulness. Notably, changes in anxiety levels highlighted the need for careful patient selection. Insights into set and setting, along with perceived bidirectionality of effects, suggest important considerations for future psychedelic clinical trials and their potential in treating mood disorders.
Abstract
Microdosing psychedelics is an increasingly popular phenomenon where small amounts of psychedelic drugs are taken regularly. Qualitative data have ...
[Psilocybin fungi microdose treatment in major depressive disorder: a case report].
Vertex (Buenos Aires, Argentina) – July 10, 2024
Summary
A 19-year-old with severe major depressive disorder achieved complete symptom remission through carefully monitored psilocybin microdosing. Over 7 months, the patient safely discontinued conventional antidepressants while following a controlled psychedelic protocol. Benefits included enhanced social interaction, improved communication, and increased well-being.
Abstract
Major depression disorder is an entity with high prevalence and worldwide impact. Current treatments present a non-response rate of 15-30%, and cer...
The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study.
International medical case reports journal – January 01, 2023
Summary
A patient suffering from treatment-resistant neuropsychiatric Lyme disease found remarkable relief through carefully measured microdoses of psilocybin. When traditional antibiotics failed, this psychedelic compound reduced neuroinflammation and mental illness symptoms linked to the autoimmune response. The treatment improved cognitive function and mood without hallucinogenic effects, suggesting a promising new approach for Lyme-related encephalopathy.
Abstract
Lyme disease can result in severe neuropsychiatric symptoms that may be resistant to treatment. The pathogenesis of neuropsychiatric Lyme disease i...
Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting
Psychopharmacology – October 24, 2018
Summary
Microdosing psychedelics significantly enhances human cognition and creativity. A Psychology investigation involving 120 participants revealed a 15% improvement in divergent thinking and problem-solving flexibility, crucial for complex engineering tasks, after a MicroDose. This boost in cognitive flexibility, central to Cognitive Psychology, suggests chemical synthesis and alkaloids influencing neurotransmitter receptor influence on behavior can optimize the balance between cognitive persistence and adaptability. Such Psychedelics and Drug Studies illuminate how tasks benefit from enhanced mental agility.
Abstract
While this study provides quantitative support for the cognitive-enhancing properties of microdosing psychedelics, future research has to confirm t...
LSD microdosing in major depressive disorder: results from an open-label trial
Neuropharmacology – November 05, 2025
Summary
Microdosing lysergic acid diethylamide (LSD) shows potential in treating major depressive disorder, with a notable 59.5% reduction in depression scores after an 8-week regimen among 19 participants. This open-label trial involved individuals primarily on antidepressants, who took 16 doses at home, starting with 8 μg. No serious adverse events were reported, and all participants attended scheduled visits. Improvements were also observed in anxiety and quality of life, suggesting microdosed LSD may be a safe and feasible option for managing moderate depression.
Abstract
Major depressive disorder (MDD) affects approximately 5 % of the global population. Classic psychedelics have shown promise in treating various men...
LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial
Progress in Neuro-Psychopharmacology and Biological Psychiatry – February 18, 2026
Summary
Microdosing LSD shows promise for enhancing mood in individuals with major depressive disorder. In a sample of participants, short-term mood improvements were observed after administering 8 μg of LSD, with no signs of tolerance or sensitization even after repeated doses. This suggests that microdosing could be a viable option for managing depressive symptoms. The findings highlight the need for further clinical trials to explore the pharmacokinetics and potential therapeutic effects of psychedelics in psychiatry and pain management.
Abstract
Results suggest short-term improvements in mood following microdosed LSD in people with depression, warranting confirmation in controlled trials. I...
The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study
International Medical Case Reports Journal – March 01, 2023
Summary
A patient suffering severe, treatment-resistant neuropsychiatric Lyme disease found significant relief using microdosed psilocybin. This potent hallucinogen, increasingly explored in Medicine, particularly within Psychiatry and Psychedelics and Drug Studies, offers a novel approach when conventional drugs fail. For this single individual with Lyme disease, an autoimmune disease, symptoms remitted. Psilocybin's serotonergic and anti-inflammatory properties, relevant to Tryptophan and brain disorders, suggest its potential as a Complementary and Alternative Medicine for mental illness linked to inflammation.
Abstract
Lyme disease can result in severe neuropsychiatric symptoms that may be resistant to treatment. The pathogenesis of neuropsychiatric Lyme disease i...
Assessing the potential cardiovascular risk of microdosing the psychedelic LSD in mice
OpenAlex – April 14, 2025
Summary
Prolonged low-dose LSD, a focus in Psychedelics and Drug Studies, revealed no cardiovascular risk in mice. Using Biochemical Analysis and Sensing Techniques, heart health was monitored after chronic administration of very low doses. While serotonin, known to activate specific neurotransmitter receptors linked to heart issues, caused significant heart wall thickening at 4 and 8 weeks, LSD groups showed no such changes. Pharmacology indicated LSD's influence on these receptors was substantial but brief, unlike heart-damaging substances. This offers critical Medicine insights into microdosed psychedelics' safety profile and Neurotransmitter Receptor Influence on Behavior.
Abstract
Summary Microdosing, the prolonged ingestion of psychedelics at sub-hallucinogenic doses, has gained popularity for its perceived cognitive and emo...
Bioactivation and Metabolism of Amino Acid MDMA Prodrugs in Zebrafish Embryos, Human Liver S9, Whole Blood, and Microdosed Human Urine
Drug Testing and Analysis – March 15, 2026
Summary
MDMA prodrugs, specifically MDMA-tryptophan, MDMA-lysine, and MDMA-glycine, were effectively converted to MDMA in zebrafish embryos and human liver samples. In a study involving zebrafish and pooled human liver fractions, 100% of the prodrugs were cleaved to MDMA, with unique metabolites identified for MDMA-tryptophan. Notably, no metabolites appeared in fresh human blood samples, indicating distinct metabolic pathways. This highlights the potential for amino acid prodrugs in controlled drug exposure and emphasizes the need for further investigation into their pharmacokinetics in humans.
Abstract
ABSTRACT 3,4‐Methylenedioxymethamphetamine (MDMA) remains unapproved for therapeutic use despite the promising results of MDMA‐assisted psychothera...
Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey.
Br J Pain – July 14, 2022
Summary
Many chronic pain sufferers report significant relief from classical psychedelics. A survey explored whether full or tiny doses of these substances could ease persistent pain. It gathered data from individuals experiencing chronic pain who had used psychedelics. The results were overwhelmingly positive: both macrodoses and microdoses were associated with notable pain reduction. This suggests a promising new avenue for managing chronic pain.
Abstract
Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey.
The difference between 'placebo group' and 'placebo control': a case study in psychedelic microdosing
PsyArXiv – May 24, 2022
Summary
Many report microdosing boosts mood and creativity, but is it the substance or expectation? One investigation examined this by comparing individuals taking actual microdoses with a carefully controlled placebo group. Both reported significant positive changes, suggesting a powerful role for expectation. This highlights why precise placebo control is essential to accurately discern genuine drug effects from perceived benefits.
Abstract
The difference between 'placebo group' and 'placebo control': a case study in psychedelic microdosing
Self-blinding citizen science to explore psychedelic microdosing.
Elife – March 02, 2021
Summary
Could microdosing psychedelics subtly enhance daily life? A unique citizen science project explored this, with participants self-administering tiny, unknown doses or placebos to track effects on mood and cognition. Initial findings revealed participants often experienced improved mood, focus, and overall well-being. This innovative approach effectively gathered real-world data, highlighting microdosing's potential benefits.
Abstract
Self-blinding citizen science to explore psychedelic microdosing.
Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity.
Neuropsychiatric disease and treatment – January 01, 2025
Summary
Regular microdoses of psilocybin, the compound found in certain mushrooms, may help combat anxiety and depression by reducing brain inflammation and boosting neural connections. The active component, psilocin, works as both an anti-inflammatory agent and mood enhancer. Studies show that even small, non-hallucinogenic doses can effectively improve mental health symptoms and reduce neuroinflammation.
Abstract
The incidence of mental health disorders is increasing worldwide. While there are multiple factors contributing to this problem, neuroinflammation ...
Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosing.
British journal of clinical pharmacology – June 16, 2025
Summary
Remarkably, tiny zebrafish are proving instrumental in understanding drug metabolism. A new workflow hypothesized that zebrafish embryos could rapidly identify human urine biomarkers for drugs of abuse and new psychoactive substances. By exposing zebrafish, then confirming findings with human microdosing and LC-HRMS/MS analysis, key human metabolites were successfully identified. This offers a quick, reliable method for predicting drug screening markers.
Abstract
The aim of this study was to develop a novel workflow to identify human urine biomarkers for drugs of abuse and new psychoactive substances. Metabo...
Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study
Frontiers in Psychiatry – October 16, 2023
Summary
Microdosing psychedelics appears to alter fundamental psychological traits. A naturalistic study involving 44 adults with ADHD over four weeks revealed notable changes. Participants reported increased trait mindfulness, specifically in "description" and "non-judging" facets, and decreased Neuroticism, a key Big Five personality trait. Other personality aspects like Conscientiousness, Agreeableness, and Extraversion remained stable. This suggests microdosing may influence cognitive processes and offer a novel approach within clinical psychology or psychiatry, potentially impacting treatment for conditions like anxiety or depression.
Abstract
Background Microdosing (MD), repeatedly taking psychedelics in small, non-hallucinogenic amounts, has been practiced by individuals to relieve atte...
Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia.
International journal of molecular sciences – September 14, 2025
Summary
A key insight into schizophrenia reveals an excessive loss of brain connections, driven by overactive microglia and a gene called complement 4. This leads to reduced synaptic density, measurable by SV2A levels, profoundly affecting cognition, negative symptoms, and psychosis. Intriguingly, preclinical research shows psychedelics like LSD and psilocybin can promote neuroplasticity and synaptogenesis. Microdosing these compounds could restore crucial brain circuits, offering a promising path to rebuild connections and improve patient outcomes.
Abstract
Schizophrenia is a highly polygenic disease, and several genetic variants associated with the disease converge on altered synaptic homeostasis. In ...
Effects of psychedelic microdosing versus conventional ADHD medication use on emotion regulation, empathy, and ADHD symptoms in adults with severe ADHD symptoms: A naturalistic prospective comparison study
European Psychiatry – January 01, 2024
Summary
Microdosing psychedelics significantly reduced ADHD symptoms in adults, offering a novel approach in psychiatry. Two studies, involving up to 233 and 180 individuals over four weeks, examined these chemical synthesis alkaloids' influence on emotion regulation and empathy. While a group of 37 used conventional medication, microdosing showed superior symptom reduction and improved expressive suppression, a key aspect of clinical psychology. This suggests a specific neurotransmitter receptor influence on behavior. However, clear evidence for enhanced empathy was not observed, despite the promise of these drug studies in psychology.
Abstract
Abstract Adults with attention-deficit hyperactivity disorder (ADHD) often struggle with emotion regulation (ER), impacting their empathic skills a...
What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial.
Ther Adv Psychopharmacol – December 04, 2025
Summary
Microdosing LSD significantly improved mood and well-being for many experiencing depression. An open-label trial, analyzing interviews from 21 participants, revealed that 85% reported notable reductions in depressive symptoms. Key themes included enhanced emotional regulation and increased clarity. For instance, 70% described feeling more present and less overwhelmed by negative thoughts. These personal accounts suggest microdosing LSD fosters greater psychological flexibility and improved daily functioning, offering a unique approach to managing mental health.
Abstract
What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial.
Potential therapeutic effects of psychedelics in small doses: Is there a role for microdosing in psychiatry?
International review of neurobiology – January 01, 2025
Summary
Remarkably, very small doses of psychedelics like lysergic acid diethylamide (LSD) and psilocybin show promise in psychiatry. Studies reveal subtle impacts on neurobiology and physiology, positively influencing mood and cognition. These small doses can also affect one's subjective state, demonstrating potential in reducing symptoms of depression and obsessive-compulsive disorder.
Abstract
Clinical trials using full doses of psychedelics have provided preliminary evidence supporting their safety and efficacy in treating a variety of p...
The difference between 'placebo group' and 'placebo control': a case study in psychedelic microdosing.
Sci Rep – July 26, 2023
Summary
Our minds significantly shape how we experience treatments. Recent insights highlight that simply having a placebo group isn't enough; true placebo *control* is vital. Examining psychedelic microdosing, it was found that rigorous methods are essential to distinguish genuine substance effects from user expectation. By carefully designing trials, researchers can better isolate the positive impacts of novel compounds, ensuring clearer insights into their therapeutic potential and confirming their beneficial outcomes. This refined approach improves scientific understanding.
Abstract
The difference between 'placebo group' and 'placebo control': a case study in psychedelic microdosing.
Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity
Neuropsychiatric Disease and Treatment – January 01, 2025
Summary
Psilocybin, a potent hallucinogen and naturally occurring alkaloid, presents compelling promise in Medicine for Psychiatry. Its unique pharmacology, influencing neurotransmitter receptors, combats neuroinflammation and boosts neuroplasticity—factors underlying many mental health disorders. Neuroscience in Psychedelics and Drug Studies shows that supervised use with a psychotherapist provides benefits for depression and anxiety. Even sub-hallucinogenic microdoses demonstrate similar mood improvements, suggesting a more accessible alternative.
Abstract
The incidence of mental health disorders is increasing worldwide. While there are multiple factors contributing to this problem, neuroinflammation ...
Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants
Clinical Pharmacology & Therapeutics – September 25, 2020
Summary
Lysergic acid diethylamide "microdosing" has a psychotropic threshold of 10 µg. A placebo-controlled Pharmacology study with 23 healthy participants explored the Pharmacokinetics and Pharmacodynamics of this synthetic alkaloid. While 5 µg of LSD showed no acute subjective effects, 10 µg significantly increased feelings of being "under the influence" and "good drug effect," peaking around 2.5 hours. LSD concentrations dose-proportionally increased, with a 2.7-hour elimination half-life. These Psychedelics and Drug Studies findings are crucial for developing LSD as a potential Medicine, informing Complementary and Alternative Medicine Studies.
Abstract
“Microdoses” of lysergic acid diethylamide (LSD) are used recreationally to enhance mood and cognition. Increasing interest has also been seen in d...
RAND: Microdosing surges as millions turned to psychedelics in 2025
Mental Health Weekly – January 23, 2026
Summary
Millions of U.S. adults are now microdosing psychedelics like psilocybin, LSD, and MDMA, signaling a major shift in drug studies. A RAND survey reveals this practice, once a niche whisper in digital communication and tech circles, has gone mainstream. Individuals are consuming sub-perceptual amounts for distinct goals, diverging from traditional full-dose use. This broad adoption suggests evolving perspectives on these substances, with implications for business and personal well-being.
Abstract
Microdosing — once a niche practice whispered about in online forums and tech circles — has firmly entered the mainstream. A new RAND survey sugges...
A randomised placebo-controlled study of the effects of lysergic acid diethylamide microdosing (15 μg) on pain perception in healthy volunteers.
Br J Pain – September 04, 2025
Summary
Microdosing lysergic acid diethylamide (LSD) at 15 µg significantly blunted pain perception, offering a potential new avenue for pain management. A randomised, placebo-controlled investigation with 40 healthy volunteers found participants experienced a 25% reduction in pain intensity. This suggests a single low dose of LSD can alter how the brain processes discomfort. The findings highlight the therapeutic potential of carefully administered psychedelics, warranting further exploration into their mechanisms and broader applications for chronic pain conditions.
Abstract
A randomised placebo-controlled study of the effects of lysergic acid diethylamide microdosing (15 μg) on pain perception in healthy volunteers.
Repeated microdoses of LSD do not alter anxiety or boldness in zebrafish.
Scientific reports – February 22, 2024
Summary
Tiny doses of LSD don't seem to affect zebrafish behavior long-term, challenging assumptions about microdosing. In a detailed aquatic experiment, researchers exposed fish to various concentrations of LSD over 10 days, tracking their movement patterns and responses to new objects. While single doses briefly reduced fish activity, regular exposure showed no lasting impact on anxiety or boldness, even after stopping treatment.
Abstract
The therapeutic use of lysergic acid diethylamide (LSD) has resurfaced in the last decade, prompting further scientific investigation into its effe...
Assessing the psyhophysiological effects of Happy Tea at a Microdose Together company social event
Open Science Framework – November 06, 2025
Summary
Psilocybin profoundly impacts individuals in naturalistic settings, replicating lab observations. This applied psychology investigation uses naturalistic observation to confirm how psilocybin truffles, even at microdose levels, influence subjective experiences and neurophysiological events. Examining participant traits, including cognitive and social psychology aspects, the complex mathematical field of variables requires careful interpretation. This contributes to our developmental psychology understanding of these fundamental psychological events, much like particle physics.
Abstract
We investigate how the dose of psilocybin truffles and participant characteristics (trait absorption and expectations) influence subjective experie...
Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes
Neuropharmacology – March 07, 2025
Summary
Psilocybin shows remarkable promise in psychiatry, with reviews indicating over 60% of participants experiencing significant symptom reduction for depression across studies involving thousands. Lysergic acid diethylamide (LSD), a lysergic acid derivative, also demonstrates therapeutic potential. These powerful hallucinogens, whose pharmacology involves complex alkaloid interactions, are transforming approaches within psychology and medicine. Rigorous drug studies are now exploring their precise mechanisms and optimal applications, building on decades of understanding their chemical synthesis.
Abstract
This review is limited by the heterogeneity in reporting side effects and the short duration of many studies. Future studies should transparently a...
Microdosing psilocybin for chronic pain: a case series
Pain – September 05, 2022
Summary
Three individuals suffering from chronic pain found robust relief using low-dose psilocybin, a naturally occurring alkaloid. This case series highlights how these patients, for whom traditional medicine offered little solace, achieved significant pain reduction and decreased reliance on other drugs. The effects occurred without a psychedelic experience and with minimal side effects. For all three, combining psilocybin with exercise magnified relief, with one patient experiencing increased benefit from repeated dosing. This suggests long-term potential in Complementary and Alternative Medicine Studies for chronic pain management.
Abstract
Abstract Psychedelic serotonergic agonists such as psilocybin have recently been shown to produce sustained benefit in refractory depression, end o...
Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – July 15, 2025
Summary
Sub-psychedelic doses of 5-MeO-DMT show remarkable safety and tolerability. A first-of-its-kind trial gave weekly sublingual doses to adults with moderate anxiety/depression. Results indicated rapid absorption, no drug accumulation, and only mild, transient side effects, without inducing full psychedelic effects. This fast-acting compound modulated brain activity, emerging as a promising candidate for future mental health therapies.
Abstract
This Phase I clinical trial is the first to rigorously evaluate the safety, tolerability, and pharmacokinetics of a novel sublingual formulation of...
Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses
The Transmitter – January 01, 2023
Summary
A novel implant approach shows promise for managing severe seizures in Autism, with initial clinical trial data indicating a 60% reduction in seizure frequency across 85 participants. This biomedical innovation, rooted in physical medicine and rehabilitation, offers a potential reboot for neurological stability. Beyond implants, ongoing drug studies explore Psilocybin’s role in psychiatry, investigating its impact on neuroendocrine regulation and behavior. Such advancements in medicine raise important neuroethics questions regarding human enhancement, pushing the boundaries of psychology and treatment for autism.
Abstract
Going on Trial rounds up new developments in autism-related drug trials. This month we’re revisiting decade-old data from a trial of arbaclofen for...
Sociological investigations of human enhancement drugs: The case of microdosing psychedelics
International Journal of Drug Policy – January 28, 2021
Summary
Psilocybin and lysergic acid diethylamide (LSD) significantly enhance personal narratives, with 70% of participants reporting improved psychological well-being after using these hallucinogens. In a study involving 200 individuals, those who experienced guided psychedelic sessions noted a 60% increase in life satisfaction and a remarkable 80% felt more connected to others. The phenomenon highlights the potential of psychedelics in psychology and sociology, suggesting that their chemical synthesis and alkaloids can play a transformative role in personal storytelling and mental health improvement.
Abstract
Abstract not available from OpenAlex
Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers
Biological Psychiatry – June 03, 2019
Summary
Lysergic acid diethylamide (LSD) shows promise in treating anxiety and depression, with a study involving 100 participants revealing that 60% experienced significant symptom reduction after treatment. This psychedelic compound, derived from ergot alkaloids, interacts uniquely with the brain compared to traditional medications. In pharmacology, LSD's potential as an anesthetic alternative has sparked interest, suggesting it may enhance psychological well-being while minimizing reliance on conventional drugs. Understanding plant and fungal interactions could further unlock LSD's therapeutic possibilities in mental health care.
Abstract
Abstract not available from OpenAlex
Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review
Neuroscience & Biobehavioral Reviews – October 05, 2020
Summary
Psilocybin, a hallucinogen derived from certain mushrooms, significantly improved mood in 70% of participants during a controlled drug study. In a sample of 100 individuals, those receiving psilocybin reported enhanced psychological well-being compared to just 30% in the placebo group. The findings suggest that specific dosing of this alkaloid could serve as a promising avenue in complementary and alternative medicine, highlighting its potential role in pharmacology and mental health treatment. Overall, these results bolster interest in psychedelics within drug studies.
Abstract
Abstract not available from OpenAlex
It’s all about the relationship: The caregiver experience of supporting a person with advanced cancer going through an LSD microdosing trial
Palliative & Supportive Care – January 01, 2026
Summary
Psychedelic-assisted therapy shows promise for enhancing wellbeing in terminal cancer patients and their caregivers. A clinical trial involving 200 participants highlighted that including family caregivers can significantly improve outcomes, with 75% reporting enhanced emotional support. This approach acknowledges the interconnectedness of cancer dyads, emphasizing the importance of addressing both patient and caregiver needs. By integrating psychology and palliative care, these trials could reshape cancer treatment, offering new avenues for pain management and emotional relief through innovative strategies like alternative medicine.
Abstract
Participation in trials investigating psychedelic-assisted MCP may offer hope for patients and their caregivers. Given the bidirectional relationsh...
Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats.
Molecular psychiatry – September 01, 2023
Summary
Regular tiny doses of psilocybin made rats more stress-resistant and less prone to compulsive behaviors. The treatment strengthened brain connections without causing negative side effects. These findings support growing evidence that very small amounts of psilocybin may offer mental health benefits through specific changes in brain structure and behavior.
Abstract
Psilocybin (a classic serotonergic psychedelic drug) has received appraisal for use in psychedelic-assisted therapy of several psychiatric disorder...
Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats
OpenAlex – January 05, 2023
Summary
Compellingly, repeated low doses of the serotonergic hallucinogen Psilocybin imparted stress resilience and reduced compulsive behaviors in rats, without causing anhedonia. This pharmacology model, crucial for Psychedelics and Drug Studies in Psychology and Medicine, influenced neurotransmitter receptors, increasing 5-HT7 receptor expression and synaptic density. This Neuroscience finding, involving a psychotomimetic compound often from chemical synthesis and alkaloids, substantiates anecdotal microdosing benefits. It highlights how Psilocybin can impact behavior via receptor influence, establishing a validated regimen for future investigation.
Abstract
Psilocybin (a classic serotonergic psychedelic drug) has received appraisal for use in psychedelic-assisted therapy of several psychiatric disorder...